Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Director | February 19, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mineralys Therapeutics, Inc.
Report date February 19, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,200 |
Reported balance
After 2026-02-19 transaction · row 1
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 6,200 · Balance 6,200 F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.06 · Expires 2036-02-19 | Direct | 8,300 |
Reported balance
After 2026-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-19 · Grant · Acquired 8,300 · Balance 8,300 F2: The stock option vests in 12 substantially equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
F2: The stock option vests in 12 substantially equal monthly installments following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 20, 2026 19:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 8,300 | $0.00 Strike: $28.06 | $0.00 |
DisclosureSEC source: 0001933414-26-000043 · wk-form4_1771634848.xml · derivative · entry 2 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2036-02-19 F2 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 19:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantCommon Stock | 6,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001933414-26-000043 · wk-form4_1771634848.xml · nonDerivative · entry 1 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · derivative · entry 13 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on July 13, 2024. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 2,742 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · derivative · entry 12 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,225 Underlying: Common Stock · 2,742 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests in 12 monthly installments following the date of grant. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 12,742 | $46.50 | $592,503.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · nonDerivative · entry 9 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 10,000 | $12.69 | $126,900.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · nonDerivative · entry 8 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 2,742 | $10.20 | $27,968.40 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · nonDerivative · entry 7 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,933 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · derivative · entry 11 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,967 Underlying: Common Stock · 6,933 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests in 12 monthly installments following the date of grant. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 1,933 | $47.28 | $91,385.67 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · nonDerivative · entry 6 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 5,000 | $46.50 | $232,500.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · nonDerivative · entry 5 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,933 Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,933 | $10.20 | $70,716.60 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · nonDerivative · entry 4 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · derivative · entry 10 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,900 Underlying: Common Stock · 15,000 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests in 12 monthly installments following the date of grant. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 5,000 | $47.08 | $235,408.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · nonDerivative · entry 3 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 10,000 | $42.43 | $424,298.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · nonDerivative · entry 2 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 15,000 | $10.20 | $153,000.00 |
DisclosureSEC source: 0001933414-25-000149 · wk-form4_1763078474.xml · nonDerivative · entry 1 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 24, 2025 18:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 32,900 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000015 · wk-form4_1740441536.xml · derivative · entry 1 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,900 Underlying: Common Stock · 32,900 shares Expires 2035-02-13 F1 · derivative.exercise_date: The stock option vests in 12 substantially equal monthly installments following the date of grant. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 16:33 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 44,000 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0001933414-24-000031 · wk-form4_1718656394.xml · derivative · entry 1 Gold Alexander M · CIK 0002026429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on July 13, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.